Antibody Drug Conjugates (ADC) – Balancing Containment and Biologic Care

In this episode, Managing Director Frederic Dietrich explores Antibody Drug Conjugates (ADCs) and the delicate balance between containment and biologic care in biopharmaceutical development.

He discusses how these advanced therapeutics – combining the precision of monoclonal antibodies with the potency of cytotoxic agents – are transforming targeted treatments in oncology, while also presenting significant challenges.

From formulation through handling, Dec Group embraces the complexity of mastering every step in the ADC journey.